NCT03506204 is a clinical trial in Pelvic Floor Muscle Weakness, sponsored by Peking Union Medical College Hospital.

Who is sponsoring NCT03506204?

NCT03506204 is sponsored by Peking Union Medical College Hospital.

What condition does NCT03506204 study?

NCT03506204 studies Pelvic Floor Muscle Weakness, Postpartum, Primiparity.

Is NCT03506204 still recruiting?

NCT03506204 is currently status unknown. Last updated 11 May 2018.

Last reviewed 2018-05-11 · How we verify

NCT03506204

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Pelvic Floor Muscle Function in Chinese Primipara, a One-year Cohort Study

Status unknown Last updated 11 May 2018

What this trial tests

trial in Pelvic Floor Muscle Weakness in 3,120 participants. Status unknown.

Timeline

10 May 2018

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	3,120
Start date	10 May 2018
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across China

Conditions studied

Pelvic Floor Muscle Weakness — all drugs for Pelvic Floor Muscle Weakness →
Postpartum — all drugs for Postpartum →
Primiparity — all drugs for Primiparity →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 50, female only, with Pelvic Floor Muscle Weakness or Postpartum. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is a prospective cohort study.The primiparas in six geographic regions of China are recruited to observe the natural recovery of pelvic floor muscle. The pelvic floor muscle function is evaluated at 6 weeks,3 months and 12 months after delivery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pelvic Floor Muscle Weakness

Currently open trials in the same condition.

NCT07243028 — Ultrasound and Electromyography Biofeedback for Pelvic Floor Muscle Training · NA · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03506204 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 11 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03506204.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing